Stock CAPR CAPRICOR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Capricor Therapeutics, Inc.

Equities

CAPR

US14070B3096

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
5.24 USD -4.38% Intraday chart for Capricor Therapeutics, Inc. -7.75% +7.16%
Jun. 04 Capricor Therapeutics Announces Positive 3-Year Efficacy Results from Hope-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy CI
May. 17 Oppenheimer Initiates Capricor Therapeutics at Outperform Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
AQ
Capricor: Q1 Earnings Snapshot
AQ
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
AQ
Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
AQ
Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences
AQ
Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13
AQ
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
AQ
Capricor Therapeutics to Present at Upcoming Investor Conferences
AQ
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
AQ
Capricor: Q4 Earnings Snapshot
AQ
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AQ
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
AQ
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29
AQ
Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization
AQ
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2
AQ
Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis
AQ
Capricor: Q3 Earnings Snapshot
AQ
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
Brain Hemorrhage Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
AQ
Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CAPR Stock
  4. News Capricor Therapeutics, Inc.
  5. Press Releases